Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-SARS-CoV-2 IgY in healthy participants
NCT04567810Phase 1Completed
- Sponsor
- Stanford University
- Start
- Sep 2020
- Primary completion
- Dec 2020
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of anti-SARS-CoV-2 IgY in coronavirus disease 2019 (COVID-19), sponsored by Stanford University. Started Sep 2020; status: completed.
02
Drugs
anti-SARS-CoV-2 IgY
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04567810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04567810.